Free tool
FAERS Monitor: Symbravo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215431 or its brand name (Symbravo, Meloxicam, Rizatriptan Benzoate). Reports on generic versions are filed under their own applications.
Reports
36
Serious
3
8% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness5
- drug ineffective5
- fatigue3
- feeling abnormal3
- headache3
- nausea3
- palpitations3
- asthenia2
- burning sensation2
- flushing2
- paraesthesia2
- tachycardia2
- abdominal pain1
- abdominal pain upper1
- amnesia1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 12 |
| 2026 | 24 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,123 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| burning sensation | 2 | 16.7 | 4.3 | 16 |
| palpitationsSignal | 3 | 15.0 | 5.1 | 27 |
| tachycardia | 2 | 13.2 | 3.4 | 12 |
| flushing | 2 | 11.5 | 3.0 | 10 |
| amnesia | 1 | 9.0 | 1.3 | 1 |
| paraesthesia | 2 | 7.4 | 1.9 | 6 |
| feeling abnormalSignal | 3 | 7.3 | 2.5 | 11 |
| dizzinessSignal | 5 | 5.9 | 2.6 | 16 |
| asthenia | 2 | 3.1 | 0.8 | 1 |
| abdominal pain upper | 1 | 2.8 | 0.4 | 0 |
| headache | 3 | 2.8 | 0.9 | 2 |
| abdominal pain | 1 | 2.5 | 0.4 | 0 |
| fatigue | 3 | 2.3 | 0.8 | 1 |
| drug ineffective | 5 | 2.2 | 1.0 | 2 |
| nausea | 3 | 2.2 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.